Management of cancer anorexia/cachexia

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.

Original languageEnglish (US)
Pages (from-to)120-122
Number of pages3
JournalSupportive Care in Cancer
Issue number2
StatePublished - Mar 1995


  • Cancer anorexia
  • Cancer cachexia
  • Corticosteroids
  • Megestrol acetate

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Management of cancer anorexia/cachexia'. Together they form a unique fingerprint.

Cite this